EU Approves First Monoclonal Antibody To Prevent RSV In All Children As U.S. Cases Surge

(Forbes) The European Commission on Friday approved the first monoclonal antibody to prevent respiratory syncytial virus (RSV) among all infants and newborns, amid a rise of cases of the highly contagious virus, which can pose a danger to infants and older adults. The European Commission approved Beyfortus, an injection manufactured by AstraZeneca and Sanofi to be given to infants from birth through their first RSV season—which typically begins in late fall—to protect against the virus, which is the most common cause of lower respiratory tract infections like bronchiolitis and pneumonia in infants.